Celldex Therapeutics, Inc. (CLDX) AI Stock Analysis

Celldex Therapeutics, Inc. is a biopharmaceutical firm based in Hampton, New Jersey, dedicated to developing therapeutic monoclonal and bispecific antibodies for inflammatory disorders and cancers. Its clinical pipeline includes CDX-0159, a Phase I monoclonal antibody targeting the receptor tyrosine kinase KIT, and CDX-1140, a human agonist monoclonal antibody targeting CD40 to activate immune cells. It also develops CDX-527, a bispecific antibody combining anti-PD-L1 and CD27 human antibodies. The company maintains research and licensing agreements with the University of Southampton, Amgen Inc., and Yale University.

Annual revenue fluctuated from $4.7M in FY2021 to $2.4M in FY2022, $6.9M in FY2023, and $7.0M in FY2024, before falling 78.6% to $1.5M in FY2025. Between FY2020 and FY2025, revenue contracted at a 5-year CAGR of -27.4%. Net losses deepened over this timeframe, widening from -$70.5M in FY2021 to -$258.8M in FY2025 as R&D expense increased from $56.8M to $245.1M. For the trailing twelve months ended June 30, 2026, revenue totaled $158,000, operating margin was -366468.2%, and diluted EPS was -$4.35, with quarterly revenue falling 97.0% year-over-year.

As of June 30, 2026, Celldex held $717.6M in cash and short-term investments and $4.9M in total debt, resulting in net cash of $712.7M. Shareholders' equity stood at $714.6M against total assets of $782.3M. The company finished the period with a current ratio of 11.82 and a debt-to-equity ratio of 0.01. Free cash flow was -$213.7M in FY2025, reflecting operating cash flow of -$210.9M and capital expenditures of $2.7M. Its share count expanded 66.7% over the trailing five years.

Celldex carries a market capitalization of $2.16B and an enterprise value of $1.73B, with a price-to-book multiple of 3.7x. For comparison, the median of its US-listed Healthcare peers trades at a trailing P/E of 24.6x, a forward P/E of 17.3x, a price-to-sales ratio of 4.1x, and an EV-to-EBITDA ratio of 12.0x. Over the past year, CLDX returned 3.7%, trailing the S&P 500 (SPY) gain of 16.8%. Over five years, the stock fell 40.4%, while the index gained 83.0%.

Celldex has 12 Strong Buy, 2 Buy, and 1 Hold recommendations from analysts, with no Sell ratings. The average price target of $63.07 implies an upside of 129.1% from the October 16, 2026 close of $27.53. For FY2026, analysts estimate revenue of $1.8M and an EPS of -$4.12. For FY2027, 10 analysts project revenue to reach $10.0M, representing 438.1% growth, with EPS of -$4.24. Celldex beat EPS estimates in 1 of the last 4 quarters, with next earnings expected on November 9, 2026.

This page is an AI-written research summary of Celldex Therapeutics, Inc. (CLDX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CLDX income statement, CLDX balance sheet, CLDX key metrics, CLDX analyst forecast, CLDX chart. See the CLDX stock overview for the latest quote and news.